Literature DB >> 19121282

H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of glucocorticoid catalysis.

Yan-ling Zhang1, Xiaotian Zhong, Zheni Gjoka, Yuanhong Li, Wayne Stochaj, Mark Stahl, Ron Kriz, James F Tobin, David Erbe, Vipin Suri.   

Abstract

Tissue specific amplification of glucocorticoid action through NADPH-dependent reduction of inactive glucocorticoid precursors by 11beta-hydroxysteroid dehydrogenase (11beta-HSD1) contributes to the development of visceral obesity, insulin resistance and Type 2 Diabetes. Hexose-6-phosphate dehydrogenase (H6PDH) is believed to supply NADPH for the reductase activity of 11beta-HSD1 in the lumen of the endoplasmic reticulum (ER), where the two enzymes are co-localized. We report here expression and purification of full-length and truncated N-terminal domain (NTD) of H6PDH in a mammalian expression system. Interestingly, both full-length H6PDH and the truncated NTD are secreted into the culture medium in the absence of 11beta-HSD1. Purified full-length H6PDH is a bi-functional enzyme with glucose-6-phosphate dehydrogenase (G6PDH) activity as well as 6-phosphogluconolactonase (6PGL) activity. Using co-immunoprecipitation experiments with purified H6PDH and 11beta-HSD1, and with cell lysates expressing H6PDH and 11beta-HSD1, we observe direct physical interaction between the two enzymes. We also show the modulation of 11beta-HSD1 directionality by H6PDH using overexpression and siRNA knockdown systems. The NTD retains the ability to interact with 11beta-HSD1 physically as well as modulate 11beta-HSD1 directionality indicating that the NTD of H6PDH is sufficient for the regulation of the 11beta-HSD1 activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19121282     DOI: 10.1016/j.abb.2008.12.004

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization.

Authors:  Ariel A Simerman; David L Hill; Tristan R Grogan; David Elashoff; Nigel J Clarke; Ellen H Goldstein; Alexa N Manrriquez; Gregorio D Chazenbalk; Daniel A Dumesic
Journal:  Fertil Steril       Date:  2014-10-24       Impact factor: 7.329

2.  Targeting the Pentose Phosphate Pathway in Syndrome X-related Cardiovascular Complications.

Authors:  Sachin A Gupte
Journal:  Drug Dev Res       Date:  2010-05-01       Impact factor: 4.360

3.  H6PD Gene Polymorphisms (R453Q and D151A) and Polycystic Ovary Syndrome: A Case-Control Study in A Population of Iranian Kurdish Women.

Authors:  Rozita Naseri; Yosra Alimoradi; Maryam Sohrabi; Mostafa Cheraghian Fard; Elahe Barzingarosi; Amir Abdolmaleki; Cyrus Jalili
Journal:  Int J Fertil Steril       Date:  2022-08-21

4.  Involvement of GR and p300 in the induction of H6PD by cortisol in human amnion fibroblasts.

Authors:  Weihua Wang; Chunming Guo; Wenjiao Li; Jianneng Li; Wangsheng Wang; Leslie Myatt; Kang Sun
Journal:  Endocrinology       Date:  2012-11-02       Impact factor: 4.736

5.  Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11β-HSD1 and H6PDH.

Authors:  Lianne Abrahams; Nina M Semjonous; Phil Guest; Agnieszka Zielinska; Beverly Hughes; Gareth G Lavery; Paul M Stewart
Journal:  J Endocrinol       Date:  2012-06-20       Impact factor: 4.286

6.  Genotype at the P554L variant of the hexose-6 phosphate dehydrogenase gene is associated with carotid intima-medial thickness.

Authors:  Thahira J Rahman; Elizabeth A Walker; Bongani M Mayosi; Darroch H Hall; Peter J Avery; John M C Connell; Hugh Watkins; Paul M Stewart; Bernard Keavney
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

7.  Effect of Glucocorticoid and 11β-Hydroxysteroid-Dehydrogenase Type 1 (11β-HSD1) in Neurological and Psychiatric Disorders.

Authors:  Seetal Dodd; David R Skvarc; Olivia M Dean; Anna Anderson; Mark Kotowicz; Michael Berk
Journal:  Int J Neuropsychopharmacol       Date:  2022-05-27       Impact factor: 5.678

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.